+++
SOMATIC SYMPTOM DISORDERS
++
Cognitive behavioral therapy has been shown to be an effective treatment for somatoform disorders by reducing physical symptoms, psychological distress, and disability.
+++
PSYCHOSEXUAL DISORDERS
++
Bremelanotide is FDA-approved for the treatment of female hypoactive sexual desire disorder in premenopausal women.
+++
SCHIZOPHRENIA SPECTRUM DISORDERS
++
There is early evidence that cannabidiol (CBD) is efficacious in improving psychotic symptoms in schizophrenia when added to existing antipsychotic treatment. This may represent a new class of therapy for psychotic disorders.
++
Allopregnanolone, a neurosteroid allosteric modulator of GABA-a receptors, was approved in 2019 for the treatment of postpartum depression.
+++
OTHER DRUG & SUBSTANCE USE DISORDERS
++
There is emerging evidence that there is a clinically distinct syndrome associated with vaping tetrahydrocannabinol (THC). Vaping-associated lung injury may result in devastating pulmonary effects and distinct pathophysiology.